ABOS
Acumen Pharmaceuticals, Inc.
$2.73
+0.16 (+6.23%)
At close · Jul 8
Market Cap
$195.01M
Shares
72,227,580
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.73
Open$2.54
Day$2.54–2.75
52W$1.15–3.60
Avg vol 30d515K
Short int1.9M · 2.6% float · 5.9d
Short vol62%
Last earningsMay 12, 2026
DataJul 2021–Jul 2026
Filing10-Q · May 12
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+19%
above
Price vs 50-day avg
+13%
above
RSI (14)
60
neutral
MACD trend
Positive
52-week position
64%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+26%
trailing
6-month return
+58%
trailing
YTD return
+29%
this year
Relative strength
+50%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Flat
1 of 85 funds reported for Jun 30 · net 0 sh shares
Insider flow
Distributing
Net -$89.5K over 90 days · 100% sells
Short interest
Falling
2.61% of float · ▼ -0.3% MoM · 5.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
85 holders — near 3-yr high, broad support
Squeeze score
76
high risk · 0–100
Fundamentals
EPS growth
−17%
Y/Y
Balance sheet
$31.6M
net cash
Quant / Vol
risk profile
Volatility
87%
annualized · 1-yr
Max drawdown
−36%
past year
ATR
6.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 12, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+19%
Bullish
Price vs 50-day avg
+13%
Bullish
RSI (14)
60
Neutral
MACD trend
Positive
Bullish
52-week position
64%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Flat
1 of 85 funds reported for Jun 30 · net 0 sh shares
Insider flow
Distributing
Net -$89.5K over 90 days · 100% sells
Short interest
Falling
2.61% of float · ▼ -0.3% MoM · 5.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
85 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $1
Now $3 · 64%
52-wk high $4
vs 200-day avg +19%
vs 50-day avg +13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ABOS
this stock
Acumen Pharmaceuticals, Inc.
|
$195.01M | +29.4% | — | — | 2.6% |
|
ONC
BeOne Medicines Ltd.
|
$437.67B | -0.6% | +22179.2% | 890.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.01B | +9.9% | +46.2% | 29.5 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.03B | -14.0% | +20.8% | 16.3 | 3.2% |
|
ARGX
Argenx SE
|
$56.84B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ABOS | +2.3% | +25.8% | +57.8% | +2.3% | +29.4% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +2.4% | +25.0% | +50.4% | +2.4% | +20.1% |